(Q40557289)

21 September 2017

title

Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori (English)

1 reference

21 September 2017

1 reference

1 reference

1 reference

Hassan Salman Roghani

1

1 reference

21 September 2017

Sedegh Massarrat

2

1 reference

21 September 2017

Mohammad Shirekhoda

3

1 reference

21 September 2017

Zia Butorab

4

1 reference

21 September 2017

language of work or name

1 reference

1 July 2003

1 reference

Journal of Gastroenterology and Hepatology

21 September 2017

published in

1 reference

21 September 2017

volume

18

1 reference

21 September 2017

issue

7

1 reference

21 September 2017

page(s)

778-782

1 reference

Regular review: treatment of Helicobacter pylori infection

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized contr

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Helicobacter pylori: novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Resistance of Helicobacter pylori to antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Consensus guidelines: agreement and debate surrounding the optimal management of Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

In vitro selection of resistant Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

In-vitro sensitivity of Campylobacter pyloridis to furazolidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03058.X

10.1046/J.1440-1746.2003.03058.X

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference